skip to main content
Idioma:

Fluvastatin mitigates SARS-CoV-2 infection in human lung cells

Zapatero-Belinchón, Francisco J. ; Moeller, Rebecca ; Lasswitz, Lisa ; van Ham, Marco ; Becker, Miriam ; Brogden, Graham ; Rosendal, Ebba ; Bi, Wenjie ; Carriquí-Madroñal, Belén ; Islam, Koushikul ; Lenman, Annasara ; Gunesch, Antonia P. ; Kirui, Jared ; Pietschmann, Thomas ; Överby, Anna K. ; Jänsch, Lothar ; Gerold, Gisa

iScience, 2021-12, Vol.24 (12), p.103469-103469, Article 103469 [Periódico revisado por pares]

United States: Elsevier Inc

Texto completo disponível

Citações Citado por
  • Título:
    Fluvastatin mitigates SARS-CoV-2 infection in human lung cells
  • Autor: Zapatero-Belinchón, Francisco J. ; Moeller, Rebecca ; Lasswitz, Lisa ; van Ham, Marco ; Becker, Miriam ; Brogden, Graham ; Rosendal, Ebba ; Bi, Wenjie ; Carriquí-Madroñal, Belén ; Islam, Koushikul ; Lenman, Annasara ; Gunesch, Antonia P. ; Kirui, Jared ; Pietschmann, Thomas ; Överby, Anna K. ; Jänsch, Lothar ; Gerold, Gisa
  • Assuntos: Drugs ; Virology
  • É parte de: iScience, 2021-12, Vol.24 (12), p.103469-103469, Article 103469
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    These authors contributed equally
    Lead contact
  • Descrição: Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Quantitative proteomics revealed that fluvastatin and other tested statins modulated the cholesterol synthesis pathway without altering innate antiviral immune responses in infected lung epithelial cells. However, fluvastatin treatment specifically downregulated proteins that modulate protein translation and viral replication. Collectively, these results support the notion that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin has a moderate beneficial effect on SARS-CoV-2 infection of human lung cells. [Display omitted] •Fluvastatin inhibits low (HCoV-229E) and high (SARS-CoV-2) pathogenic coronaviruses•SARS-CoV-2 infection does not affect statin-induced cholesterol biosynthesis arrest•Statin treatment does not alter SARS-CoV-2 innate immune responses in vitro•Fluvastatin downregulates protein translation and viral replication pathways Drugs; Virology
  • Editor: United States: Elsevier Inc
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.